Fifty patients with iron-deficiency anaemia were treated by total-dose infusion of iron-dextran. 
Introduction
Oral iron therapy will effect a rapid return to normal of the peripheral blood haemoglobin level in the great majority of cases of irondeficiency anaemia. Since satisfactory treatment of iron deficiency implies replacement of the total body iron deficit however, it is now realized that several months of continuous oral therapy are required to bring about full replacement of the depleted iron stores. Many patients default from treatment before the total body iron deficit has been corrected and patients with continuing blood loss, such as can occur from hiatus hernia, colonic diverticulosis or severe menorrhagia, may require almost permanent oral iron therapy to maintain iron balance. We feel that these factors justify the parenteral treatment of iron-deficiency anaemia in selected cases.
A number of iron preparations for intravenous use have been produced. Earlier intravenous preparations such as colloidal ferric hydroxide and colloidal ferric oxide proved to be too toxic (Goethsch, Moore & Minnich, 1946) and the first practical form of intravenous therapy was a saccharated iron oxide compound (Nissim, 1947) but even with this substance a significant number of severe toxic reactions occurred (Barrit & Swain, 1953; Librach, 1953; Nissim, 1954; Ross, 1957; Bare & Sullivan, 1960) .
There are two iron compounds available for intramuscular injection, iron-dextran and ironsorbitol-citric acid complex. Both have been used extensively and their safety and effectiveness are established (Baird & Podmore, 1954; Scott & Govan, 1954; Grimes & Hutt, 1957; Andersson, 1961) .
Replacement of the total body iron deficit by intramuscular iron therapy requires multiple injections which are tedious to both patient and doctor. Further disadvantages of the intramuscular preparations are loss of iron by local sequestration or in the urine, painful injections which tend to occur particularly in patients whose muscle mass is small, allergic reactions and skin staining.
In an attempt to simplify parenteral iron therapy Basu (1963) introduced the single total dose method of administration using iron-dextran, giving the total estimated body requirement of iron in a single intravenous infusion. Subsequent reports (Marchasin & Wallerstein, 1964; Varde, 1964; Bonnar, 1965; Dawson, Goldthorpe & Spencer, 1965; Manson, 1966) (Will & Groden, 1968) .
Materials and methods
The diagnosis of iron-deficiency anaemia, as in previous reports (Will & Groden, 1965) , was based on peripheral blood findings of low haemoglobin, low mean corpuscular haemoglobin concentration and hypochromia of the stained peripheral blood film associated with abnormally low serum iron level, raised total iron-binding capacity and absence of stainable iron in the marrow. A satisfactory response to iron therapy was the ultimate confirmation of the diagnosis. Standard haematological techniques were used (Dacie & Lewis, 1963) and serum iron estimations were made by the technique of Ramsay (1957) . Tables 1 and 2 summarize the aetiological factors present and the initial haematological details.
The quantities of iron-dextran ranged from 27 to 68ml (1.35-3-4g iron). The iron preparation was given diluted in 250-1000ml isotonic saline. The infusion was run at the rate of 10-15 drops per minute for the first 5 min while the patient was observed for evidence of systemic reaction. The rate was then increased to [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] drops a minute until the infusion was completed. Thirty minutes before the infusion was begun forty of the patients were given an antihistamine by intramuscular injection, promethazine hydrochloride (Phenergan) 25mg. After the irondextran infusion the patient was instructed not to take any form of iron therapy. 
Results
In all patients a satisfactory reticulocyte response occurred and was followed by a progressive rise in haemoglobin. In the majority of patients a significant reticulocyte response had begun by the 4th day after infusion and the peak response usually occurred between the 8th and 10th days.
The mean haemoglobin increments after each of the first 3 weeks of treatment were 1 5g (range 0-3-35 g), 2-7 g (range 1-0-5-2 g) and 36 g (range 1 6-68 g). When the patients are separated into three groups on the basis of initial haemoglobin levels the rate of response to irondextran is shown to be related to the severity of the anaemia. These results are shown in Table 3 . No. of (g/100 ml) at: (g/100 ml) One patient defaulted after 14 days. In the remaining forty-nine patients for whom full data are available the haemoglobin had reached normal levels by the 9th week. When seen 16 weeks after the infusion the remaining patient had a normal haemoglobin level.
In the ten patients investigated no significant change from the pre-infusion results were detected in the tests of bleeding time, clotting time, one-stage prothrombin time, capillary fragility, thromboplastin generation or partial thromboplastin time. The ESR estimations remained unchanged and there was no evidence of intravascular haemolysis following infusion. No difficulty was experienced in carrying out ABO and Rh grouping and cross matching of blood in any of the ten patients using blood samples withdrawn immediately after completion of the irondextran infusions (Table 4) .
There were no general systemic reactions during or after the infusions. One patient complained of frontal headaches coming on half-an-hour after completion of the infusion. Superficial thrombophlebitis occurred in five patients, only two of whom had received an antihistamine injection before treatment.
Discussion
The absence of signs of iron toxicity in the immediate post-infusion period when the plasma iron-dextran content is at its highest is in keeping with the suggestion that the complex circulates in the blood stream as inert material until it is taken up by the reticulo-endothelial system (Golberg, 1958) . The prompt occurrence of a reticulocyte response with peak values attained between the 8th and 10th days shows clearly that despite the firm union of the iron with the dextran, there is no delay in iron utilization. The haemoglobin increments measured over the first 3 weeks after treatment exceed those reported in similar cases by other workers using a variety of parenteral iron preparations (Kartchner & Holmstrom, 1950; Scott & Govan, 1951; Jennison & Ellis, 1954; Scott & Govan, 1954; Scott, 1956; Andersson, 1961) .
The initial rate of rise of haemoglobin reported is considerably faster than the figure of 2g/ 100ml at the end of 3 weeks which is regarded by Coleman et al. (1955) as a significant response to oral iron therapy, while Goldberg (1967) The adequacy of the haematological response in iron deficiency anaemia to total-dose irondextran infusion has been previously reported by a number of authors (Gartlan, 1964; Varde, 1964; Basu, 1965; Bonnar, 1965; Clay et al., 1965; Goldthorp, Spencer & Dawson, 1965; Lane & Scott, 1965; Manson, 1965) , but these studies related to patients seen in obstetric and gynaecological practice. The results in the present series indicate that a similar satisfactory response can be obtained in patients within a wide age range and suffering from a variety of clinical conditions.
No severe reactions occurred during or following the infusions. The incidence of local phlebitis was low and when it occurred was mild in type. The time taken to complete the infusion ranged from 30 min to several hours. No increase in complications occurred in the patients given the iron-dextran more rapidly and we doubt the rationale of prolonging the infusion. Indeed we gained the impression that the incidence of thrombophlebitis was lower in the patients rapidly infused.
Blood grouping and cross matching and the erythrocyte sedimentation rate were not influenced by the treatment in the ten patients investigated. The coagulation mechanism was not impaired nor was there evidence of intravascular haemolysis. It seems that with the dosage of iron-dextran required to treat iron deficiency the amount of dextran present in the circulation after the infusion is insufficient to cause enhanced rouleaux-formation or to alter the clotting mechanism when this is tested by the methods described.
